Sertindole : a review of its use in schizophrenia.

Abstract

Oral sertindole (Serdolect) is an atypical antipsychotic approved in the EU for once-daily use in patients with schizophrenia who are intolerant to at least one other antipsychotic agent. Extensive data from post-marketing studies do not indicate an excess of overall mortality with sertindole. Sertindole is at least as effective as haloperidol and risperidone in the treatment of neuroleptic-responsive schizophrenia. Sertindole improves negative symptoms, and is also effective for the treatment of neuroleptic-resistant schizophrenia. Sertindole is generally well tolerated and is associated with a low rate of extrapyramidal symptoms (EPS). Thus, sertindole is a useful option in the treatment of patients with schizophrenia.

• Authors: David Murdoch, Gillian M Keating
• Journal: CNS drugs (CNS Drugs) Vol. 20 Issue 3 Pg. 233-55 ( 2006) ISSN: 1172-7047 [Print] New Zealand
• PMID: 16529528 (Publication Type: Evaluation Study, Journal Article, Review)

Chemical References

• Antipsychotic Agents
• Imidazoles
• Indoles
• sertindole

Topics

• Antipsychotic Agents (pharmacology, therapeutic use)
• Humans
• Imidazoles (pharmacology, therapeutic use)
• Indoles (pharmacology, therapeutic use)
• Medical Informatics (methods, statistics & numerical data)
• Schizophrenia (drug therapy)